Oric Pharmaceuticals Inc   (ORIC)
Other Ticker:  
Price: $14.6600 $1.92 15.071%
Day's High: $15.375 Week Perf: 22.68 %
Day's Low: $ 13.45 30 Day Perf: 33.39 %
Volume (M): 961 52 Wk High: $ 15.38
Volume (M$): $ 14,094 52 Wk Avg: $7.46
Open: $13.57 52 Wk Low: $4.09

 Market Capitalization (Millions $) 842
 Shares Outstanding (Millions) 57
 Employees 51
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -93
 Cash Flow (TTM) (Millions $) -200
 Capital Exp. (TTM) (Millions $) 3

Oric Pharmaceuticals Inc
Oric Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company that specializes in developing targeted cancer treatments. The company was founded in 2014 and has its headquarters in Durham, North Carolina. Its mission is to develop innovative cancer therapies that are designed to overcome tumor resistance and improve patient outcomes.

The company's approach to cancer treatment is based on the concept of oncogene addiction. Oncogene addiction is a phenomenon where cancer cells become dependent on a particular oncogenic driver pathway for survival and proliferation. Oric's drug development programs are focused on inhibiting these oncogenic pathways to induce cancer cell death or halt tumor growth.

Oric has two lead drug candidates in clinical development, ORIC-101 and ORIC-53 ORIC-101 is a potent and selective inhibitor of the serine/threonine kinase AKT, which is involved in multiple oncogenic signaling pathways. The drug is being evaluated in phase 1b and 2 clinical trials for the treatment of solid tumors harboring AKT mutations, amplifications, or other dysregulations. ORIC-533, on the other hand, is a small molecule inhibitor of the CD73 enzyme, which plays a role in tumor immune evasion. The drug is being developed for the treatment of various solid tumors, including bladder, breast, and ovarian cancer.

In addition to its clinical pipeline, Oric has a preclinical portfolio of development-stage programs targeting various oncogenic drivers, such as KRAS and EGFR. The company leverages various scientific approaches, including machine learning algorithms and functional genomics, to identify and validate new cancer targets.

Oric has established partnerships with several leading academic institutions, such as Memorial Sloan Kettering Cancer Center and the University of California, San Francisco, to advance its drug development programs. The company also collaborates with other biopharmaceutical companies, such as Taiho Pharmaceutical and AstraZeneca, to explore new drug combinations and treatment approaches.

Overall, Oric Pharmaceuticals Inc. is a promising biotech company that is focused on developing precision cancer therapies that could potentially transform cancer treatment and improve patient outcomes.

   Company Address: 240 E. Grand Ave South San Francisco 94080 CA
   Company Phone Number: 388-5600   Stock Exchange / Ticker: NASDAQ ORIC
   ORIC is expected to report next financial results on March 15, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report


ORIC Pharmaceuticals Grants Inducement Options and Restricted Stock Units to New Employees, Demonstrating Confidence in Company's Growth Potential

Published Fri, Feb 2 2024 9:30 PM UTC

ORIC Pharmaceuticals, a leading clinical-stage oncology company, made an exciting announcement today regarding the granting of inducement options and restricted stock units to two new non-executive employees. The grant serves as a testament to the company's commitment to attracting top talent and further developing treatments that target therapeutic resistance in t...

Financing Agreement

ORIC Pharmaceuticals Raises $125 Million and Fortifies Workforce, Empowering Oncology Breakthroughs

Published Mon, Jan 22 2024 1:30 PM UTC

ORIC Pharmaceuticals Secures $125 Million in Private Placement Financing and Reinforces Workforce with Inducement Grants, Reinforcing Commitment to Oncology Breakthroughs
In a bid to strengthen its position in the field of oncology research and development, ORIC Pharmaceuticals has recently announced significant milestones. The clinical stage oncology company has success...

Clinical Study

Advancing Therapeutic Frontiers: ORIC-944 Demonstrates Potential Best-in-Class Profile for Metastatic Prostate Cancer Treatment

Published Mon, Jan 8 2024 1:30 PM UTC

Metastatic prostate cancer, a devastating disease that affects thousands of men worldwide, requires innovative approaches to improve patient outcomes. ORIC Pharmaceuticals, a pioneering biopharmaceutical company, has recently provided compelling initial Phase 1b data for their promising therapeutic candidate, ORIC-944, in metastatic prostate cancer. This article focuses on t...

Oric Pharmaceuticals Inc

ORIC Pharmaceuticals Inc Releases 3rd Quarter 2023 Earnings, Despite Operating Loss and Increased Net Deficit

Oric Pharmaceuticals Inc has recently made some significant moves in the market, with its shares gaining 11.15% in the last five trading days. Not only that, but the company's shares have also seen a remarkable increase of 187.8% compared to the previous year. Currently trading on the NASDAQ, the stock is 19.1% above its 52-week average. These positive developments have caught the attention of shareholders and investors.
However, while the stock price is on the rise, recent financial reports from Oric Pharmaceuticals Inc paint a slightly different picture. The company's operating loss for the July to September 30, 2023 reporting cycle amounted to $-28.682 million. This figure is higher than the operating loss of $-25.694 million for the same period in 2022. It is crucial to note that the lack of revenue has contributed to a significant net deficit of $-25.478 million for the third quarter of 2023, up from $-24.829 million in Q3 of 2022.


Fueling Growth: ORIC Pharmaceuticals' Inducement Grants Drive Positive Momentum in Shares

Published Fri, Nov 3 2023 8:30 PM UTC

ORIC Pharmaceuticals, a clinical stage oncology company, has recently granted inducement incentives to a non-executive employee, showcasing their commitment to talent acquisition and development. This press release sheds light on the details of the grant and its impact on the company's shares and overall performance.

1. Overview of the Inducement Grants:



About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com